CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2025 Apr 02, 16:00

USD/JPY Forecast: Analyzing Market Trends and Economic Indicators

Forex
Tommy Yap 2025 Apr 02, 16:00

Morning Note: U.S. Tariffs Shake Markets, Nikkei Sinks & Swiss Inflation Data Awaits

Morning Note USD
Frances Wang 2025 Apr 01, 16:00

Silver news today: Why has the silver price been volatile recently?

Commodities
three barrels of oil, neftechka, and American dollars against the background of a wooden table
Tommy Yap 2025 Mar 31, 21:00

Morning Note: US Jobs Data, Oil Steady on Tariffs, MicroStrategy BTC Bet

Oil Morning Note Cryptocurrencies
Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Japan retail 
Tommy Yap 2025 Mar 29, 21:00

Morning Note: Japan Retail, China PMI, Germany Inflation

Japan Morning Note China
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices

Info

Spread

0.05

Spread (%)

0.8446 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt openen

Donderdag

13:31 - 19:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

847543744

Uitstaande aandelen

137143008

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.83

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot